Arnold S. Freedman, MD

    Arnold S. Freedman, MD

    Professor of Medicine at Harvard Medical School and from the Department of Medical Oncology at the Dana-Farber Cancer Institute in Boston, MA
    • Would you restart rituximab as part of a new chemotherapy regimen for this patient with DLBCL? Thursday, December 1st, 2016

      This month, Arnold S. Freedman, MD, answers a question about restarting rituximab as part of a new chemotherapy regimen for a patient with diffuse large B-cell lymphoma. Clinical Dilemma: In 2012, I treated a young man with follicular lymphoma with four cycles of bendamustine/rituximab. He developed prolonged neutropenia (presumed rituximab associated) that lasted eight months. [...]

    SHARE